Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years for breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.
Atossa is the only company in the WORLD attempting to conquer breast cancer in the manner that they have stated: “The best way to treat a disease is to prevent it in the first place.” They are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density. Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer. However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal of their topical endoxifen program is to treat high breast density with a local, topical drug.
Atossa is also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.
Their proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Their patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.
Here's What The Experts Are Saying
Vista Exclusive Content
“A Sinking Feeling” – Vista Partners Daily Market Recap 11/12/2018
US stocks sank today, with all three major indices dropping throughout the day and eventually ending solidly in the red by the close of trade. The S&P 500 lost 1.97%, and the Nasdaq tumbled 2.78%. The Dow had dropped 2.32% by the end of the
“Vista’s View – A Weekly FREE Market Update 11-10-18″…Now Available!
Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 11-10-18!” Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink. Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that
“Back Down” – Vista Partners Daily Market Recap 11/9/2018
US stocks were headed back down on Friday after the impressive gains made during the midweek session. The S&P 500 slipped 0.92% (25.82 points) while the Nasdaq had dropped 1.65% (123.98 points) as trade ended for the day. The Dow also ended the day in
Company News Around The Web
25 October 2018 | 1:10 pm
Report: Exploring Fundamental Drivers Behind Atossa Genetics,...
NEW YORK, Oct. 25, 2018 -- In new independent research repor...
18 October 2018 | 8:00 pm
"...Amidst Market Volatility" Vista Partners' October Macroeconomic...
SAN FRANCISCO, CA / ACCESSWIRE / October 18, 2018 / Vista Pa...
11 October 2018 | 12:00 pm
Atossa Genetics Completes Enrollment in Phase 2 Study...
Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biophar...
26 September 2018 | 1:05 pm
''Superfirms' Domination Influences Economic Factors''
SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2018 / Vista ...
25 September 2018 | 12:20 pm
Report: Developing Opportunities within Crocs, NetApp, Gannett...
NEW YORK, Sept. 25, 2018 -- In new independent research repo...
14 September 2018 | 1:10 pm
An Interview with Atossa CEO Steven Quay...
SAN FRANCISCO, CA / ACCESSWIRE / September 14, 2018 / The Gr...
|Day Low - High||-|
|Year Low - High||-|